
Cinzia Solinas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/853090/publications.pdf Version: 2024-02-01



CINZIA SOLINAS

#	ARTICLE Assessing Tumor Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and	IF	CITATIONS
1	Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Cenitourinary, Carcinomas, and Primary Brain Tumors, Advances in Anatomic Pathology, 2017, 24, Assessing Tumor-Inflitrating Lymphocytes in Solid Tumors. A Practical Review for Pathologists and	4.3	530
2	Assessing Tumor-inflitrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	4.3	469
3	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	5.0	182
4	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncolmmunology, 2017, 6, e1257452.	4.6	169
5	Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open, 2017, 2, e000255.	4.5	118
6	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Seminars in Cancer Biology, 2018, 52, 151-157.	9.6	108
7	The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open, 2020, 5, e000544.	4.5	95
8	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast, 2017, 35, 142-150.	2.2	87
9	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	4.8	80
10	A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine and Growth Factor Reviews, 2020, 54, 8-23.	7.2	77
11	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treatment Reviews, 2017, 57, 8-15.	7.7	75
12	LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. Cancers, 2019, 11, 1213.	3.7	75
13	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Journal of Clinical Investigation, 2021, 131, .	8.2	70
14	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2017, 120, 13-21.	4.4	56
15	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Translational Oncology, 2020, 13, 410-422.	3.7	52
16	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers, 2019, 11, 305.	3.7	51
17	Significance of TIM3 expression in cancer: From biology to the clinic. Seminars in Oncology, 2019, 46, 372-379.	2.2	49
18	Cancer immunotherapy-associated hypophysitis. Seminars in Oncology, 2018, 45, 181-186.	2.2	47

CINZIA SOLINAS

#	Article	IF	CITATIONS
19	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. Translational Oncology, 2020, 13, 100811.	3.7	46
20	Adjuvant trastuzumab: a 10-year overview of its benefit. Expert Review of Anticancer Therapy, 2017, 17, 61-74.	2.4	40
21	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine, 2019, 39, 226-238.	6.1	36
22	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treatment Reviews, 2020, 84, 101947.	7.7	35
23	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. Critical Reviews in Oncology/Hematology, 2017, 110, 106-116.	4.4	33
24	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Letters, 2019, 450, 88-97.	7.2	33
25	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis and Therapy, 2021, 25, 409-424.	3.8	33
26	The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?. Targeted Oncology, 2018, 13, 113-123.	3.6	26
27	Radiomics and "radi-…omics―in cancer immunotherapy: a guide for clinicians. Critical Reviews in Oncology/Hematology, 2020, 154, 103068.	4.4	26
28	Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. Targeted Oncology, 2020, 15, 25-35.	3.6	25
29	Targeting <scp>CTLA</scp> â€4 in cancer: Is it the ideal companion for <scp>PD</scp> â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	5.1	23
30	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. Cancer Treatment Reviews, 2017, 53, 138-145.	7.7	20
31	Role of cardiac <scp>MRI</scp> in the diagnosis of immune checkpoint inhibitorâ€associated myocarditis. International Journal of Cancer, 2022, 151, 1860-1873.	5.1	19
32	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43.	4.4	18
33	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 4.	3.0	17
34	Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342095417.	1.1	15
35	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. Critical Reviews in Oncology/Hematology, 2018, 126, 135-144.	4.4	14
36	Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Targeted Oncology, 2021, 16, 553-568.	3.6	13

CINZIA SOLINAS

#	Article	IF	CITATIONS
37	Gender-specific aspects related to type of fertility preservation strategies and access to fertility care. ESMO Open, 2020, 5, e000771.	4.5	13
38	A review of immune checkpoint blockade in breast cancer. Seminars in Oncology, 2021, 48, 208-225.	2.2	11
39	Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1167.	2.8	8
40	Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues. Methods in Molecular Biology, 2018, 1845, 139-157.	0.9	6
41	Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?. Cancers, 2021, 13, 1655.	3.7	6
42	Abstract 1624: Reliability of immune biomarker assessment in breast cancer: A report on interobserver variability from studies at a single institution. Cancer Research, 2018, 78, 1624-1624.	0.9	3
43	Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?. Blood, 2016, 128, 5983-5983.	1.4	0
44	Abstract A62: Investigating the role of follicular helper T cells, B cells and CXCL13 in breast cancer-associated tertiary lymphoid structures. , 2017, , .		0
45	Abstract 4689: Immune functions and regulation of follicular helper CD4+CXCR5+T cells in human breast cancer. , 2018, , .		0
46	Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial. , 2019, , .		0